Loss of 10q26.1–q26.3 in association with 7q34–q36.3 gain or 17q24.3–q25.3 gain predict poor outcome in pediatric medulloblastoma

Medulloblastoma (MB) is the most common malignant brain tumor of childhood. We have investigated for novel chromosomal imbalances and prognostic markers of pediatric MB. Forty MBs out of 64, were analyzed using high resolution prometaphase comparative genomic hybridization. Chromosome 10q26.1–q26.3 loss combined with 17q24.3–q25.3 gain and/or 7q34–q36.3 gain in tumors predicted poor patient’s survival. A minimal deleted region of 14.12 cM at 10q26.1–q26.3 was refined by LOH analysis. We propose a new prognostic marker for pediatric MB patient risk stratification based on the presence of 10q26.1–q26.3 loss plus 17q24.3–q25.3 gain and/or 7q34–q36.3 gain associations.

► We perform a genome analysis on medulloblastoma to identify new prognostic markers.
► 10q loss or 7q or 17q gains predict poor outcome in medulloblastoma.
► No correlation between 10q26.1 loss and DMBT1 gene expression.
► MYC and MYCN or 3p21.2–p21.3 amplification predicts a reduced patients’ survival.
► Differently from other reports 17p loss does not influence patient’s clinical outcome.